person · Reporting owner
Kerr Giles Francis Bertram
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Director | July 02, 2019 | July 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date July 02, 2019 · Filed July 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2029-07-02 | Direct | 124,000 |
Reported balance
After 2019-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-02 · Grant · Acquired 124,000 · Balance 124,000 F1: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2019 Filed Jul 3, 2019 17:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 124,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001104659-19-039323 · a4.xml · derivative · entry 1 Kerr Giles Francis Bertram · CIK 0001689112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Ordinary Shares · 124,000 shares Expires 2029-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 17:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 124,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-042321 · a4.xml · derivative · entry 1 Kerr Giles Francis Bertram · CIK 0001689112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Ordinary Shares · 124,000 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 17:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 144,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001104659-17-043262 · a4.xml · derivative · entry 1 Kerr Giles Francis Bertram · CIK 0001689112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 Underlying: Ordinary Shares · 144,000 shares Expires 2027-07-03 F1 · derivative.exercise_price: The exercise price was converted from GBP0.58 based on the closing midpoint exchange rate for the U.S. dollar on the trading day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:30 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 288,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001104659-16-160132 · a4.xml · derivative · entry 1 Kerr Giles Francis Bertram · CIK 0001689112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Ordinary Shares · 288,000 shares Expires 2026-11-29 F1 · derivative.exercise_price: The exercise price was converted from GBP0.65 based on the closing midpoint exchange rate for the U.S. dollar on the trading day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 72,000 Ordinary Shares on November 29, 2017 and will be exercisable as to the remainder in monthly installments of 9,000 Ordinary Shares on the twenty-ninth of each month from December 29, 2017 through November 29, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.